Interim 2023/2024 Season Influenza Vaccine Effectiveness in Primary and Secondary Care in the United Kingdom

IF 4.3 4区医学 Q1 INFECTIOUS DISEASES

Influenza and Other Respiratory Viruses Pub Date : 2024-05-21 DOI:10.1111/irv.13284

Heather Whitaker, Beth Findlay, Jana Zitha, Rosalind Goudie, Katie Hassell, Josie Evans, Panoraia Kalapotharakou, Utkarsh Agrawal, Beatrix Kele, Mark Hamilton, Catherine Moore, Rachel Byford, Julia Stowe, Chris Robertson, Anastasia Couzens, Gavin Jamie, Katja Hoschler, Kathleen Pheasant, Elizabeth Button, Catherine Quinot, Tim Jones, Sneha Anand, Conall Watson, Nick Andrews, Simon de Lusignan, Maria Zambon, Christopher Williams, Simon Cottrell, Kimberly Marsh, Jim McMenamin, Jamie Lopez Bernal

{"title":"Interim 2023/2024 Season Influenza Vaccine Effectiveness in Primary and Secondary Care in the United Kingdom","authors":"Heather Whitaker, Beth Findlay, Jana Zitha, Rosalind Goudie, Katie Hassell, Josie Evans, Panoraia Kalapotharakou, Utkarsh Agrawal, Beatrix Kele, Mark Hamilton, Catherine Moore, Rachel Byford, Julia Stowe, Chris Robertson, Anastasia Couzens, Gavin Jamie, Katja Hoschler, Kathleen Pheasant, Elizabeth Button, Catherine Quinot, Tim Jones, Sneha Anand, Conall Watson, Nick Andrews, Simon de Lusignan, Maria Zambon, Christopher Williams, Simon Cottrell, Kimberly Marsh, Jim McMenamin, Jamie Lopez Bernal","doi":"10.1111/irv.13284","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>We report 2023/2024 season interim influenza vaccine effectiveness for three studies, namely, primary care in Great Britain, hospital settings in Scotland and hospital settings in England.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A test negative design was used to estimate vaccine effectiveness.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Estimated vaccine effectiveness against all influenzas ranged from 63% (95% confidence interval 46 to 75%) to 65% (41 to 79%) among children aged 2–17, from 36% (20 to 49%) to 55% (43 to 65%) among adults 18–64 and from 40% (29 to 50%) to 55% (32 to 70%) among adults aged 65 and over.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>During a period of co-circulation of influenza A(H1N1)pdm09 and A(H3N2) in the United Kingdom, evidence for effectiveness of the influenza vaccine in both children and adults was found.</p>\n </section>\n </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.13284","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Influenza and Other Respiratory Viruses","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/irv.13284","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Background

We report 2023/2024 season interim influenza vaccine effectiveness for three studies, namely, primary care in Great Britain, hospital settings in Scotland and hospital settings in England.

Methods

A test negative design was used to estimate vaccine effectiveness.

Results

Estimated vaccine effectiveness against all influenzas ranged from 63% (95% confidence interval 46 to 75%) to 65% (41 to 79%) among children aged 2–17, from 36% (20 to 49%) to 55% (43 to 65%) among adults 18–64 and from 40% (29 to 50%) to 55% (32 to 70%) among adults aged 65 and over.

Conclusions

During a period of co-circulation of influenza A(H1N1)pdm09 and A(H3N2) in the United Kingdom, evidence for effectiveness of the influenza vaccine in both children and adults was found.

Abstract Image

查看原文本刊更多论文

英国 2023/2024 年流感季节初级和二级护理中流感疫苗的临时有效性。

背景：我们报告了三项研究的 2023/2024 季度中期流感疫苗有效性，即英国的初级保健、苏格兰的医院环境和英格兰的医院环境：方法：采用阴性试验设计来估计疫苗效果：在 2-17 岁的儿童中，疫苗对所有流感的估计有效率为 63%（95% 置信区间为 46% 至 75%）至 65%（41% 至 79%）；在 18-64 岁的成年人中，疫苗对所有流感的估计有效率为 36%（20% 至 49%）至 55%（43% 至 65%）；在 65 岁及以上的成年人中，疫苗对所有流感的估计有效率为 40%（29% 至 50%）至 55%（32% 至 70%）：结论：在甲型 H1N1 pdm09 流感和甲型 H3N2 流感在英国同时流行期间，有证据表明流感疫苗对儿童和成人都有效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Influenza and Other Respiratory Viruses 医学-病毒学

CiteScore

7.20

自引率

4.50%

发文量

120

审稿时长

6-12 weeks

期刊介绍： Influenza and Other Respiratory Viruses is the official journal of the International Society of Influenza and Other Respiratory Virus Diseases - an independent scientific professional society - dedicated to promoting the prevention, detection, treatment, and control of influenza and other respiratory virus diseases. Influenza and Other Respiratory Viruses is an Open Access journal. Copyright on any research article published by Influenza and Other Respiratory Viruses is retained by the author(s). Authors grant Wiley a license to publish the article and identify itself as the original publisher. Authors also grant any third party the right to use the article freely as long as its integrity is maintained and its original authors, citation details and publisher are identified.